EULAR 2025 Streamlines Rheumatoid Arthritis DMARD Management to Nine Recommendations
🔓 Free Teaser Guideline Rheumatology / Immunology Confirmatory Grade: Moderate
Smolen JS, Edwards CJ, Konzett V, et al.
Jun 13, 2026 · Published in: Annals of the Rheumatic Diseases
New EULAR guidelines redefine RA management with DMARDs.
Chronic Steroids and Age Predict JAK Inhibitor Discontinuation in RA
Analysis Rheumatology / Immunology Hypothesis-generating Grade: Low
Martinez-Molina C, Frade-Sosa B, Diaz-Torné C, et al.
Aug 31, 2026 · Published in: RMD Open
Glucocorticoids and age affect JAK inhibitor retention in RA.
Who Can Taper Abrocitinib? Early Response and Atopic Burden Predict Success
Analysis Rheumatology / Immunology Hypothesis-generating Grade: Low
Wang Y, Qin H, Gao Y, et al.
Aug 25, 2026 · Published in: Annals of Medicine
Can personalized abrocitinib dosing enhance atopic dermatitis management?
M2e Nanoparticle Vaccines: Rational Design for Universal Influenza A
Analysis Rheumatology / Immunology Hypothesis-generating Grade: Very Low
Bourlon L, Morlieras J, Marche PN, et al.
Aug 20, 2026 · Published in: Expert Review of Vaccines
M2e-based nanoparticles aim for universal influenza A protection.
Non-TNFi Biologics Linked to Lower PsA Risk
Analysis Rheumatology / Immunology
Kougkas N, Sotiriou E, Deligeorgakis D, et al.
Aug 12, 2026 · Published in: Rheumatology (Oxford, England)
Non-TNFi biologics may lower PsA risk in psoriasis.
Daratumumab plus anti-CD20 rescues refractory recurrent FSGS after transplant
Analysis Rheumatology / Immunology Hypothesis-generating Grade: Low
Leon J, Ducrocq E, Lafargue MC, et al.
Aug 9, 2026 · Published in: Kidney International Reports
Can dual antibody therapy offer a lifeline for transplant patients with recurrent FSGS?
Calcineurin Inhibitor Triple Therapy Ranks Highest for Lupus Nephritis Remission
Analysis Rheumatology / Immunology Confirmatory Grade: Moderate
Aug 5, 2026 · Published in: Lupus
Triple therapy with Tacrolimus or Voclosporin excels in lupus nephritis remission.
Dupilumab After JAK Inhibitor Withdrawal: Small Real-World Signal
Analysis Rheumatology / Immunology Hypothesis-generating Grade: Very Low
Wang Q, Yang G, Li Y, et al.
Jul 16, 2026 · Published in: Frontiers in Immunology
Switching from JAK inhibitors to dupilumab shows promise in atopic dermatitis management.
JAK Inhibitors Show Limited Efficacy in Refractory JIA Uveitis
Analysis Rheumatology / Immunology Hypothesis-generating Grade: Very Low
Baquet-Walscheid K, Wortmann C, Rothaus K, et al.
Jul 11, 2026 · Published in: Pediatric Rheumatology Online Journal
Janus kinase inhibitors show limited efficacy in JIA-associated uveitis.
2025 ACR SLE Guideline Prioritizes Hydroxychloroquine and Glucocorticoid Minimization
Guideline Rheumatology / Immunology Practice-changing Grade: Low
Sammaritano LR, Askanase A, Bermas BL, et al.
Jul 4, 2026 · Published in: Arthritis & Rheumatology (Hoboken, N.J.)
New guidelines unify SLE treatment strategies for better outcomes.
Obinutuzumab Improves Response in Active Non-Renal SLE
Analysis Rheumatology / Immunology Practice-changing Grade: High
Furie RA, Dall'Era M, Vital EM, et al.
Mar 6, 2026 · Published in: N Engl J Med
Obinutuzumab improves SLE outcomes in the recent ALLEGORY trial.